<DOC>
	<DOCNO>NCT00517465</DOCNO>
	<brief_summary>This 4 arm study evaluate pharmacokinetics , pharmacodynamics , safety tolerability multiple ascending dos R1511 compare placebo patient type 2 diabetes mellitus . The start dose R1511 100mg po bid 5 1/2 day ; dose escalate subsequent group patient potential maximum 1200mg po bid 5 1/2 day satisfactory assessment blind safety , tolerability , pharmacokinetic pharmacodynamic data previous dose . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Multiple Ascending Dose Study R1511 Patients With Type 2 Diabetes Mellitus .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>adult patient , 1865 year age ; type 2 diabetic patient ; naive antidiabetic therapy , take current antidiabetic therapy &gt; =2 week first treatment . type 1 diabetes mellitus ; clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>